BACKGROUND: Environmental exposures to indoor allergens are major contributors to asthma symptoms, particularly in inner cities. The effectiveness of household allergen reduction as an adjunct to National Asthma Education Prevention Program guideline-based pharmacologic therapy in asthma has not been prospectively studied. OBJECTIVE: To study the effect of individualized allergen reduction on ability to reduce asthma pharmacologic therapy over 40 weeks. METHODS: We performed a randomized controlled trial to determine the effect of multifaceted indoor allergen avoidance measures on the ability to reduce asthma controller therapy in adults and children residing in New York City who were both sensitized and exposed to at least 1 indoor allergen. Asthma treatment and control were optimized in all subjects before randomization. RESULTS: A total of 125 subjects were randomized to receive individualized household allergen reduction and 122 received a sham intervention. Subjects in the intervention group significantly reduced all measured allergen levels (cat, dog, dust mite allergens in the bedroom, cockroach and mouse allergens in the kitchen and bedroom); those in the control group reduced only dust mite and mouse allergens in the bedroom and cockroach allergen in the kitchen. Participants in the intervention arm reduced National Asthma Education Prevention Program-based therapy from step 4.4 at randomization to 3.50 postintervention (range, 0-6); participants in the control arm reduced medication from step 4.4 to 3.4 (P = .76). There were no differences in other measured asthma outcomes. CONCLUSIONS: Targeted allergen avoidance measures do not allow for reduction in asthma pharmacologic therapy compared with usual care in patients already receiving optimal controller therapy.
RCT Entities:
BACKGROUND: Environmental exposures to indoor allergens are major contributors to asthma symptoms, particularly in inner cities. The effectiveness of household allergen reduction as an adjunct to National Asthma Education Prevention Program guideline-based pharmacologic therapy in asthma has not been prospectively studied. OBJECTIVE: To study the effect of individualized allergen reduction on ability to reduce asthma pharmacologic therapy over 40 weeks. METHODS: We performed a randomized controlled trial to determine the effect of multifaceted indoor allergen avoidance measures on the ability to reduce asthma controller therapy in adults and children residing in New York City who were both sensitized and exposed to at least 1 indoor allergen. Asthma treatment and control were optimized in all subjects before randomization. RESULTS: A total of 125 subjects were randomized to receive individualized household allergen reduction and 122 received a sham intervention. Subjects in the intervention group significantly reduced all measured allergen levels (cat, dog, dust mite allergens in the bedroom, cockroach and mouse allergens in the kitchen and bedroom); those in the control group reduced only dust mite and mouse allergens in the bedroom and cockroach allergen in the kitchen. Participants in the intervention arm reduced National Asthma Education Prevention Program-based therapy from step 4.4 at randomization to 3.50 postintervention (range, 0-6); participants in the control arm reduced medication from step 4.4 to 3.4 (P = .76). There were no differences in other measured asthma outcomes. CONCLUSIONS: Targeted allergen avoidance measures do not allow for reduction in asthma pharmacologic therapy compared with usual care in patients already receiving optimal controller therapy.
Authors: D L Rosenstreich; P Eggleston; M Kattan; D Baker; R G Slavin; P Gergen; H Mitchell; K McNiff-Mortimer; H Lynn; D Ownby; F Malveaux Journal: N Engl J Med Date: 1997-05-08 Impact factor: 91.245
Authors: Ginger L Chew; Matthew S Perzanowski; Stephen M Canfield; Inge F Goldstein; Robert B Mellins; Lori A Hoepner; Maxine Ashby-Thompson; Judith S Jacobson Journal: J Allergy Clin Immunol Date: 2007-10-22 Impact factor: 10.793
Authors: Robert A Nathan; Christine A Sorkness; Mark Kosinski; Michael Schatz; James T Li; Philip Marcus; John J Murray; Trudy B Pendergraft Journal: J Allergy Clin Immunol Date: 2004-01 Impact factor: 10.793
Authors: Kathleen M Donohue; Umaima Al-alem; Matthew S Perzanowski; Ginger L Chew; Alina Johnson; Adnan Divjan; Elizabeth A Kelvin; Lori A Hoepner; Frederica P Perera; Rachel L Miller Journal: J Allergy Clin Immunol Date: 2008-11 Impact factor: 10.793
Authors: Ginger L Chew; Matthew S Perzanowski; Rachel L Miller; Juan C Correa; Lori A Hoepner; Carlos M Jusino; Mark G Becker; Patrick L Kinney Journal: Environ Health Perspect Date: 2003-08 Impact factor: 9.031
Authors: Ellen F Crain; Michelle Walter; George T O'Connor; Herman Mitchell; Rebecca S Gruchalla; Meyer Kattan; George S Malindzak; Paul Enright; Richard Evans; Wayne Morgan; James W Stout Journal: Environ Health Perspect Date: 2002-09 Impact factor: 9.031
Authors: Elizabeth C Matsui; Matthew Perzanowski; Roger D Peng; Robert A Wise; Susan Balcer-Whaley; Michelle Newman; Amparito Cunningham; Adnan Divjan; Mary E Bollinger; Shuyan Zhai; Ginger Chew; Rachel L Miller; Wanda Phipatanakul Journal: JAMA Date: 2017-03-14 Impact factor: 56.272
Authors: William J Sheehan; Jonathan M Gaffin; David B Peden; Robert K Bush; Wanda Phipatanakul Journal: J Allergy Clin Immunol Date: 2017-12 Impact factor: 10.793
Authors: Wanda Phipatanakul; Petros Koutrakis; Brent A Coull; Choong-Min Kang; Jack M Wolfson; Stephen T Ferguson; Carter R Petty; Mihail Samnaliev; Amparito Cunningham; William J Sheehan; Jonathan M Gaffin; Sachin N Baxi; Peggy S Lai; Perdita Permaul; Liming Liang; Peter S Thorne; Gary Adamkiewicz; Kasey J Brennan; Andrea A Baccarelli; Diane R Gold Journal: Contemp Clin Trials Date: 2017-06-12 Impact factor: 2.226
Authors: Anna Pomés; Geoffrey A Mueller; Thomas A Randall; Martin D Chapman; L Karla Arruda Journal: Curr Allergy Asthma Rep Date: 2017-04 Impact factor: 4.806
Authors: Jeffery M Franklin; Jocelyn R Grunwell; Alice C Bruce; Robin C Smith; Anne M Fitzpatrick Journal: Ann Allergy Asthma Immunol Date: 2017-05-04 Impact factor: 6.347